PL2854826T3 - Lactobacillus reuteri atcc pta 6475 do stosowania dla zapobiegania utracie kości u ssaków - Google Patents

Lactobacillus reuteri atcc pta 6475 do stosowania dla zapobiegania utracie kości u ssaków

Info

Publication number
PL2854826T3
PL2854826T3 PL13800449T PL13800449T PL2854826T3 PL 2854826 T3 PL2854826 T3 PL 2854826T3 PL 13800449 T PL13800449 T PL 13800449T PL 13800449 T PL13800449 T PL 13800449T PL 2854826 T3 PL2854826 T3 PL 2854826T3
Authority
PL
Poland
Prior art keywords
mammals
prevention
treatment
bone loss
atcc pta
Prior art date
Application number
PL13800449T
Other languages
English (en)
Inventor
Eamonn Connolly
Robert Allen Britton
Laura Rae MCCABE
Original Assignee
Biogaia Ab
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab, Michigan State University filed Critical Biogaia Ab
Publication of PL2854826T3 publication Critical patent/PL2854826T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13800449T 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 do stosowania dla zapobiegania utracie kości u ssaków PL2854826T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04
EP13800449.4A EP2854826B9 (en) 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 for use in prevention or treatment of bone loss in mammals
PCT/SE2013/050646 WO2013184064A1 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals

Publications (1)

Publication Number Publication Date
PL2854826T3 true PL2854826T3 (pl) 2019-06-28

Family

ID=49712339

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13800449T PL2854826T3 (pl) 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 do stosowania dla zapobiegania utracie kości u ssaków
PL18202594T PL3456334T3 (pl) 2012-06-04 2013-06-04 Bakterie kwasu mlekowego do stosowania dla zapobiegania ubytkowi masy kostnej u ssaków

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18202594T PL3456334T3 (pl) 2012-06-04 2013-06-04 Bakterie kwasu mlekowego do stosowania dla zapobiegania ubytkowi masy kostnej u ssaków

Country Status (16)

Country Link
US (4) US20150150917A1 (pl)
EP (2) EP2854826B9 (pl)
JP (1) JP6193981B2 (pl)
KR (2) KR20150028968A (pl)
CN (1) CN104755091B (pl)
AU (2) AU2013272330B2 (pl)
CA (1) CA2875841C (pl)
DK (2) DK2854826T3 (pl)
ES (2) ES2711427T3 (pl)
HR (1) HRP20190162T1 (pl)
HU (1) HUE042643T2 (pl)
LT (1) LT2854826T (pl)
PL (2) PL2854826T3 (pl)
SI (1) SI2854826T1 (pl)
TR (1) TR201901771T4 (pl)
WO (1) WO2013184064A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) * 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2021009389A (es) * 2019-02-05 2021-11-17 Elanco Us Inc Lactobacillus modificado geneticamente y usos del mismo.
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
JP7596301B2 (ja) * 2019-12-02 2024-12-09 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用
KR102937770B1 (ko) * 2023-08-09 2026-03-12 국립한국교통대학교산학협력단 골다공증 억제 균주 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511502A2 (en) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotic therapies using lactobacillus reuteri
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP2604689B1 (en) * 2005-07-26 2015-01-21 Nestec Ltd. Anti-obesity agent and anti-obesity food
EP2061483A1 (en) * 2006-09-07 2009-05-27 McGill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
US20080254011A1 (en) 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Also Published As

Publication number Publication date
US10537598B2 (en) 2020-01-21
WO2013184064A1 (en) 2013-12-12
US20170128501A1 (en) 2017-05-11
US20150150917A1 (en) 2015-06-04
EP2854826B1 (en) 2018-11-14
EP2854826A4 (en) 2016-07-06
HUE042643T2 (hu) 2019-07-29
DK3456334T3 (da) 2021-01-25
JP2015526389A (ja) 2015-09-10
US20190142879A1 (en) 2019-05-16
US10232001B2 (en) 2019-03-19
CA2875841C (en) 2021-02-02
ES2711427T8 (es) 2019-06-20
ES2847424T3 (es) 2021-08-03
TR201901771T4 (tr) 2019-03-21
CA2875841A1 (en) 2013-12-12
PL3456334T3 (pl) 2021-05-04
CN104755091B (zh) 2020-07-21
KR102191537B1 (ko) 2020-12-16
SI2854826T1 (sl) 2019-03-29
AU2018200524B2 (en) 2019-07-18
DK2854826T3 (en) 2019-03-11
EP3456334B1 (en) 2020-11-11
KR20150028968A (ko) 2015-03-17
JP6193981B2 (ja) 2017-09-06
EP3456334A1 (en) 2019-03-20
LT2854826T (lt) 2019-02-11
HK1211847A1 (en) 2016-06-03
EP2854826B9 (en) 2019-05-08
ES2711427T3 (es) 2019-05-03
US9968643B2 (en) 2018-05-15
CN104755091A (zh) 2015-07-01
AU2013272330A1 (en) 2015-01-15
EP2854826A1 (en) 2015-04-08
HRP20190162T1 (hr) 2019-04-05
KR20200044134A (ko) 2020-04-28
AU2018200524A1 (en) 2018-02-15
US20180200313A1 (en) 2018-07-19
AU2013272330B2 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
LT2854826T (lt) Lactobacillus reuteri atcc pta 6475, skirtas panaudoti kaulų masės praradimo prevencijai arba gydymui žinduoliuose
ZA201207377B (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
ZA201507275B (en) Probiotic strains for use in treatment or prevention of osteoporosis
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
EP2440209A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
SG11201504542PA (en) Probiotic strains for the treatment and/or prevention of diarrhœa
ZA201408055B (en) Compositions and methods for the treatment of local pain
SMT202300283T1 (it) Lactobacillus reuteri mm4-1a per l’uso nel trattamento o nella prevenzione dei disturbi dello spettro autistico
PL2276498T3 (pl) Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii
PL2457576T3 (pl) Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
SI2854910T1 (sl) Nivoji ceramida pri zdravljenju in preprečevanju okužb
IL238126A0 (en) Compositions for the treatment and prevention of obesity
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
PL2731584T3 (pl) Zastosowanie związków oligosacharydowych do zapobiegania i leczenia patologicznych blizn
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
EP2559432A4 (en) MEANS FOR THE PREVENTION AND TREATMENT OF ACUTE AND CHRONIC PANCREATITIS
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
GB201100023D0 (en) Immunogenic compositions for the prevention and/or treatment of human metapneumovirus (hmpv)
UA63764U (ru) Применение экстракта из листьев сныти обыкновенной в качестве лечебно-профилактического средства с гепатопротекторным действием
GB201104965D0 (en) Gpr119 agonists for use in the treatment or prevention of dyslipidaemia in humans